Acute myelomonocytic leukemia M4
MONDO:0018871An acute leukemia characterized by the proliferation of both neutrophil and monocyte precursors. (WHO, 2001)
Also known as: AML M4, AMML, AMMoL, acute M4 myeloid leukaemia, acute M4 myeloid leukemia, acute myelomonocytic leukaemia, acute myelomonocytic leukaemia (FAB type M4), acute myelomonocytic leukemia
3094 clinical trials for this condition and its sub-types, 4 tagged with Acute myelomonocytic leukemia M4 itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New combo therapy shows promise for older leukemia patients
Disease control OngoingThis study tested a combination of two drugs, azacitidine and gemtuzumab ozogamicin, in 133 older adults (age 60+) with untreated acute myeloid leukemia. The goal was to see how well the treatment could put the cancer into remission and improve survival. The approach uses chemoth…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Gentler chemo approach shows promise for tough blood cancers in older patients
Disease control OngoingThis study looks at whether lower doses of the chemotherapy drug CPX-351 can help older patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that have come back or not responded to other treatments. The goal is to control the disease while being gentler o…
Phase 2 • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Can a 'Priming' drug boost chemo for tough leukemia?
Disease control OngoingThis phase 2 trial tests whether adding the drug decitabine to standard chemotherapy improves remission rates in adults with acute myeloid leukemia (AML) who have less favorable genetic risk. Decitabine is given before chemo to try to make cancer cells more sensitive. About 178 p…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC